New indications for BeiGene PD-1 inhibitor for first-line treatment of hepatocellular carcinoma
海角七号
发表于 2024-1-2 20:27:48
333
0
0
On January 2, 2024, Baekje Shenzhou announced its PD-1 inhibitor Baekzeon& Reg; The new indication of (tirizizumab) has been approved by the National Medical Products Administration (NMPA) of China for first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC) patients. At this point, 12 indications for tirizizumab have been approved in China.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- AbbVie sues for infringement again, BeiGene denies allegations: this move is intended to prevent project development
- Merck PD-1 inhibitor CRDA approved as a new indication for melanoma treatment in China
- Domestic innovative drug leader faces another 'patent challenge': AbbVie accuses BTK degradation agent of infringement, causing BeiGene's stock price to suffer a setback
- BeiGene denies AbbVie's accusation of "stealing trade secrets": will launch a firm defense and development projects will not be interrupted as a result
- BeiGene responds to AbbVie's lawsuit alleging theft of trade secrets: with the intention of obstructing the development process
- BeiGene executive Yin Min is under investigation after previously serving at AstraZeneca | News
- A senior executive of BeiGene has been investigated, and insiders say that the reason for the investigation is unrelated to BeiGene
- BeiGene executive Yin Min is suspected of smuggling and cooperating with the investigation
- Lilly: The first and only non covalent (reversible) BTK inhibitor, Jeparil, has been approved in China
- Puyin International: downgraded BeiGene A-share rating to 'hold', maintaining target price of 181 yuan
-
"영비릉: 2024회계연도 영업수입 동기대비 8% 감소"영비릉은 2024회계연도 재무제보를 발표했다.2024 회계연도 매출은 149억5500만 유로로 전년 동기 대비 8% 감소했습니다.이익은 31억 500만 유로입니다.이익률은 ...- 勇敢的树袋熊1
- 3 일전
- Up
- Down
- Reply
- Favorite
-
계면신문기자 장우발 4분기의 영업수입이 하락한후 텐센트음악은 다시 성장으로 돌아왔다. 11월 12일, 텐센트음악은 최신 재보를 발표했다.2024년 9월 30일까지 이 회사의 3분기 총수입은 70억 2천만 위안으로 전년 ...
- 勇敢的树袋熊1
- 그저께 15:27
- Up
- Down
- Reply
- Favorite
-
본사소식 (기자 원전새): 11월 14일, 다다그룹 (나스닥코드: DADA) 은 2024년 3분기 실적보고를 발표했다. 수치가 보여준데 따르면 고품질발전전략에 지속적으로 전념하고 사용자체험을 끊임없이 최적화하며 공급을 ...- 家养宠物繁殖
- 어제 15:21
- Up
- Down
- Reply
- Favorite
-
11월 12일 소식에 따르면 소식통에 따르면 아마존은 무료스트리밍서비스 Freevee를 페쇄하고 일부 종업원과 프로를 구독서비스 Prime Video로 이전할 계획이다. 올해 초 아마존이 내놓은 몇 편의 대형 드라마의 효 ...- 度素告
- 그저께 13:58
- Up
- Down
- Reply
- Favorite
